Project profile — Support to COVID-19 diagnostics

• Africa, regional (20.00%)
• America, regional (20.00%)
• Asia, regional (20.00%)
• Oceania, regional (20.00%)
• Europe, regional (20.00%)

• Basic Health: Infectious disease control (12250) (50.00%)
• Health: COVID-19 control (12264) (50.00%)

• Gender equality (significant objective)
• Environmental sustainability (cross-cutting) (not targeted)
• Participatory development and good governance (not targeted)
• Trade development (not targeted)
• Biodiversity (not targeted)
• Climate change mitigation (not targeted)
• Climate Change Adaptation (not targeted)
• Urban issues (not targeted)
• Desertification (not targeted)
• Children's issues (not targeted)
• Youth Issues (not targeted)
• Disaster Risk Reduction(DRR) (not targeted)
• Indigenous Issues (not targeted)
• Disability (not targeted)
• Nutrition (not targeted)
• ICT as a tool for development (not targeted)

This project supports the Foundation for Innovative New Diagnostics (FIND) in accelerating the roll-out of safe, affordable, and effective COVID-19 diagnostics in Low- and Lower-Middle Income Countries. It contributes to the global COVID-19 response set out in the Access to COVID-19 Tools Accelerator Diagnostics Partnership. Project activities include: (1) developing rapid and affordable COVID-19 tests for use in lower-income countries; and (2) building and deploying new testing and market shaping strategies to meet the changing needs of the pandemic response. This project represents additional funds provided in response to the COVID-19 pandemic. The description and expected results are the same.

The expected outcomes of this project include: (1) increased capacity of manufacturers to research and develop rapid diagnostic tests; and (2) enhanced access to simple, accurate, and affordable COVID-19 tests for Lower-Middle Income Countries.

Results achieved as of May 2023 include: (1) procured 193 million tests through the Access to COVID-19 Tools Accelerator Diagnostics Consortium for Lower-Middle Income Countries; and (2) reduced COVID-19 test pricing. This includes reducing the polymerase chain reaction (PCR) test price from US$20-30, to less than $10 per test, and quality-assured rapid diagnostic tests from more than US$5 to less than US$1.

• Proactive disclosure
• Related activities:
• Support to COVID-19 Diagnostics
• Support to COVID-19 Diagnostics